Background and Objective: The current study aimed to evaluate cardiovascular risk factors, haematological and biochemical parameters, and serum endocan concentrations in lichen planus (LP) patients. Methods: This study was conducted with 86 cases, including 43 LP patients and 43 healthy controls. Cardiovascular risk factors, haematological and biochemical parameters, and endocan levels were evaluated. Results: The serum endocan concentrations of LP patients were not significantly different from those of the healthy controls (p > 0.05). There were no significant differences in the serum endocan levels according to classification by cardiovascular risk factors and smoking history (p > 0.05). In the LP group, white blood cell count, platelet distribution width and monocyte count/high-density lipoprotein cholesterol ratios were significantly higher when compared to the healthy controls (p < 0.05). The LP group had a lower mean platelet volume than the healthy controls (p < 0.05). Conclusions: Serum endocan levels did not change significantly in patients with LP, and there were significant differences in haematological and biochemical parameters.

Keywords:
Haematological parameters, Lichen planus, Biochemical parameters, Cardiovascular risk factors, Endocan
1.
Arias-Santiago S, Buendia-Eisman A, Aneiros-Fernandez J, Giron-Prieto MS, Gutierrez-Salmeron MT, Garcia-Mellado V, et al: Lipid levels in patients with lichen planus: a case-control study. J Eur Acad Dermatol Venereol 2011;25:1398-1401.
2.
Seyhan M, Ozcan H, Sahin I, Bayram N, Karincaoglu Y: High prevalence of glucose metabolism disturbance in patients with lichen planus. Diabetes Res Clin Pract 2007;77:198-202.
3.
Arias-Santiago S, Buendia-Eisman A, Aneiros-Fernandez J, Giron-Prieto MS, Gutierrez-Salmeron MT, Mellado VG, et al: Cardiovascular risk factors in patients with lichen planus. Am J Med 2011;124:543-548.
4.
Saleh N, Samir N, Megahed H, Farid E: Homocysteine and other cardiovascular risk factors in patients with lichen planus. J Eur Acad Dermatol Venereol 2014;28:1507-1513.
5.
Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al: ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996;271:20458-20464.
6.
Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al: Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25-37.
7.
Bechard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al: Human endothelial cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167:3099-3106.
8.
Yang J, Yang Q, Yu S, Zhang X: Endocan: a new marker for cancer and a target for cancer therapy. Biomed Rep 2015;3:279-283.
9.
Kose M, Emet S, Akpinar TS, Kocaaga M, Cakmak R, Akarsu M, et al: Serum endocan level and the severity of coronary artery disease: a pilot study. Angiology 2015;66:727-731.
10.
Balta I, Balta S, Koryurek OM, Demirkol S, Mikhailidis DP, Celik T, et al: Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol 2014;70:291-296.
11.
Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M, et al: Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol 2013;169:1066-1070.
12.
Middel P, Lippert U, Hummel KM, Bertsch HP, Artuc M, Schweyer S, et al: Expression of lymphotoxin-alpha by keratinocytes: a further mediator for the lichenoid reaction. Pathobiology 2000;68:291-300.
13.
Sezer E, Ozugurlu F, Ozyurt H, Sahin S, Etikan I: Lipid peroxidation and antioxidant status in lichen planus. Clin Exp Dermatol 2007;32:430-434.
14.
Aly DG, Shahin RS: Oxidative stress in lichen planus. Acta Dermatovenerol Alp Pannonica Adriat 2010;19:3-11.
15.
Flammer AJ, Ruschitzka F: Psoriasis and atherosclerosis: two plaques, one syndrome? Eur Heart J 2012;33:1989-1991.
16.
Canpolat U, Cetin EH, Cetin S, Aydın S, Akboga MK, Yayla C, et al: Association of monocyte-to-HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost 2016;22:476-482.
17.
Kim DS, Shin D, Lee MS, Kim HJ, Kim DY, Kim SM, et al: Assessments of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in Korean patients with psoriasis vulgaris and psoriatic arthritis. J Dermatol 2016;43:305-310.
18.
Kim DS, Lee J, Kim SH, Kim SM, Lee MG: Mean platelet volume is elevated in patients with psoriasis vulgaris. Yonsei Med J 2015;56:712-718.
19.
Neves FS, Carrasco S, Goldenstein-Schainberg C, Goncalves CR, de Mello SB: Neutrophil hyperchemotaxis in Behçet's disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol 2009;28:1403-1410.
20.
Arias-Santiago S, Gutiérrez-Salmerón MT, Castellote-Caballero L, Buendía-Eisman A, Naranjo-Sintes R: Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study. J Am Acad Dermatol 2010;63:420-429.
21.
Gisondi P, Tessari G, Conti A, et al: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73.
22.
Dreiher J, Shapiro J, Cohen AD: Lichen planus and dyslipidaemia: a case-control study. Br J Dermatol 2009;161:626-629.
23.
Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, et al: Expression and distribution of endocan in human tissues. Biotech Histochem 2012;87:172-178.
24.
Shin JW, Huggenberger R, Detmar M: Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 2008;112:2318-2326.
25.
Delehedde M, Devenyns L, Maurage C-A, Vives RR: Endocan in cancers: a lesson from a circulating dermatan sulfate proteoglycan. Int J Cell Biol 2013;2013:705027.
26.
Vendrell J, Broch M, Vilarrasa N, Molina A, Gomez JM, Gutierrez C, et al: Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004;12:962-971.
27.
Ataseven A, Ugur Bilgin A: Effects of isotretinoin on the platelet counts and the mean platelet volume in patients with acne vulgaris. Sci World J 2014;2014:156464.
28.
Safak S, Uslu AU, Serdal K, Turker T, Soner S, Lutfi A: Association between mean platelet volume levels and inflammation in SLE patients presented with arthritis. Afr Health Sci 2014;14:919-924.
29.
Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS: Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008;102:653-657.
30.
Ayca B, Akin F, Okuyan E: Platelet to lymphocyte ratio as a prognostic marker in primary percutaneous coronary intervention. Platelets 2015;26:816.
31.
Boyraz I, Koc B, Boyaci A, Tutoglu A, Salman H, Ozkan H: Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF. Int J Clin Exp Med 2014;7:2912-2915.
32.
Kanbay M, Solak Y, Unal HU, Kurt YG, Gok M, Cetinkaya H, et al: Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014;46:1619-1625.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.